Related Experiment Video

Updated: May 22, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma

El Mehdi Tazi1, Ismail Essadi, Hind M'rabti

  • 1Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.

North American Journal of Medical Sciences
|April 28, 2012
PubMed
Abstract

Insights

Sorafenib demonstrates improved survival in advanced hepatocellular carcinoma (HCC), marking a new era for molecularly targeted therapies. Further research aims to personalize treatments for better outcomes in this global malignancy.

Area of Science:

  • Oncology
  • Hepatology
  • Molecular Biology

Background:

  • Advanced hepatocellular carcinoma (HCC) is a significant global health concern, ranking as the sixth most common cancer and third leading cause of cancer mortality.
  • Traditional systemic chemotherapy and hormone therapy have shown limited efficacy in improving survival rates for HCC patients.

Purpose of the Study:

  • To review the clinical development and impact of Sorafenib, a molecularly targeted agent, in advanced HCC.
  • To discuss the emergence of molecularly targeted agents as a new standard of care for advanced HCC.

Main Methods:

  • Review of placebo-controlled, randomized phase III trials evaluating Sorafenib in advanced HCC.
  • Analysis of ongoing studies investigating combinations of targeted agents and chemotherapy for HCC treatment.

Main Results:

  • Sorafenib has demonstrated significant survival benefits in advanced HCC, establishing a new benchmark for clinical trials.
  • The success of Sorafenib heralds the era of molecularly targeted agents in HCC treatment.

Conclusions:

  • Sorafenib's proven survival benefits in advanced HCC signify the beginning of molecular-targeted therapy in this disease.
  • Numerous molecularly targeted agents are currently in active clinical development for HCC, offering new therapeutic avenues.
Keywords:
ABT 869BevacizumabBrivanibErlotinibHepatocellular carcinomaPazopanibSorafenibSunitinibSystemic treatmentTargeted therapy

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...